Ensign Peak Advisors
GBT

Ensign Peak Advisors’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Ensign Peak Advisors’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-168,180
Closed -$11.5M – 2339
2022
Q3 		$11.5M Buy
168,180
+75,416
+81% +$4.16M 0.03% 355
2022
Q2 		$2.96M Buy
92,764
+74,654
+412% +$2.19M 0.01% 671
2022
Q1 		$627K Sell
18,110
-55,542
-75% -$1.66M ﹤0.01% 1455
2021
Q4 		$2.16M Buy
73,652
+73,552
+73,552% +$2.28M ﹤0.01% 927
2021
Q3 		$3K Sell
100
-62,689
-100% -$1.84M ﹤0.01% 1851
2021
Q2 		$2.2M Buy
62,789
+32,100
+105% +$1.25M ﹤0.01% 1077
2021
Q1 		$1.25M Sell
30,689
-108,569
-78% -$4.99M ﹤0.01% 1337
2020
Q4 		$6.03M Buy
139,258
+20,458
+17% +$1.01M 0.01% 551
2020
Q3 		$6.55M Buy
118,800
+29,180
+33% +$1.85M 0.02% 544
2020
Q2 		$5.66M Buy
89,620
+24,570
+38% +$1.69M 0.02% 582
2020
Q1 		$3.32M Buy
65,050
+36,288
+126% +$2.43M 0.01% 628
2019
Q4 		$2.29M Buy
+28,762
New +$1.7M 0.01% 997

Other funds holding GBT

BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Ensign Peak Advisors's GBT Position: Q4 2022 in Review

Ensign Peak Advisors sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 168,180 shares — an estimated $11.5M sold.

Ensign Peak Advisors first reported a position in GBT in Q4 2019 and held it in 12 quarters. The position peaked at $11.5M in Q3 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

  • Ensign Peak Advisors reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 168,180 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $11.5M.
  • Ensign Peak Advisors first reported a position in Global Blood Therapeutics, Inc. in Q4 2019 and held it in 12 quarters.
  • Ensign Peak Advisors's Global Blood Therapeutics, Inc. position peaked at $11.5M in Q3 2022.
  • 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on Ensign Peak Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.